Abstract:Topic: 32. Platelet disorders Background: Patients with steroid-resistant or relapsed immune thrombocytopenia (ITP) have an increased risk of bleeding and impaired quality of life. Baricitinib, a selective and reversible inhibitor of Janus-associated kinase 1 (JAK1) and JAK2, can modulate multiple cytokine signalling pathways involved in self-reactive innate and adaptive immune responses. Splenic macrophages phagocytose IgG-opsonized platelets and then present the internalized platelet antigens to activate T cells and B cells, maintaining the self-reactive adaptive immune response. Baricitinib inhibits IFN-induced antigen presentation by innate immune cells and subsequent T-cell activation, and has been observed to alleviate the B-cell abnormalities and antibody production. Accordingly, baricitinib might alleviate both innate and adaptive immune disorders in ITP. Aims: To explore the efficacy and safety of baricitinib as second-line therapy for patients with steroid-resistant or relapsed ITP. Methods: This single-arm, open-label, phase 2 trial was conducted at Peking University People’s Hospital. Adult patients with steroid-resistant or relapsed ITP who had a platelet count <30×10⁹/L, or a platelet count <50×10⁹/L with clinically significant bleeding, were eligible for this study. The patients received baricitinib 4 mg daily for 6 months. The primary endpoint was durable response at the 6-month follow-up. Efficacy endpoints were analysed in the modified intention-to-treat population, which included all enrolled patients except for those who withdrew consent or post hoc objectively did not meet the eligibility criteria (e.g. a diagnosis of secondary ITP after enrolment, de novo infections, comorbidities or laboratory abnormalities before baricitinib administration). Safety profiles were analysed in patients receiving at least one dose of baricitinib. This study is registered with ClinicalTrials.gov (NCT05446831). Results: A total of 35 patients were enrolled, of which 28 were included in the modified intention-to-treat population. Durable response was achieved in 20 patients (71.4%, 95% confidence interval, 51.3 to 86.8), and initial response was achieved in 18 patients (64.3%). The median time from initial treatment to response was 13 days (IQR, 6.75-22.5). Patients receiving baricitinib showed a median platelet count of over 50 × 109/L since the 4-week follow-up, which then remained stable at 72-81×109/L throughout the treatment period. The detailed response profile and platelet counts for each participant are shown in a swimmer’s plot (Figure 1). Twenty-two patients (78.6%) received concomitant medications at baseline, including corticosteroids (14/28, 50.0%) and TPO-RAs (12/28, 42.9%). For some patients responding to treatment, these medications were tapered or discontinued. At the last visit, 12 patients (42.9%) were receiving concomitant medications, with 3 patients (10.7%) receiving corticosteroids and 7 patients receiving TPO-RAs (25.0%). Patients receiving baricitinib also reported improved quality of life, which was measured by the Primary ITP-Patient Assessment Questionnaire (ITP-PAQ) scales. The most common adverse events were infections (6/28, 21.4%). Treatment discontinuation due to an adverse event was reported in 1 (3.6%) patient.Summary/Conclusion: This is the first study reporting JAK inhibition as a therapy for ITP. Baricitinib at 4 mg daily was well tolerated and potentially effective in the treatment of steroid-resistant or relapsed ITP. This finding may contribute to refined second-line management of ITP, and future randomized, controlled trials are warranted. Keywords: Idiopathic thombocytopenic purpura (ITP), Clinical trial, Janus Kinase inhibitor

Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition

Baricitinib protects ICIs-related myocarditis by targeting JAK1/STAT3 to regulate Macrophage polarization

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy

Novel therapies in CIDP

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story

Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world data

Unveiling the Potential of JAK Inhibitors in Inflammatory Bowel Disease

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

Successful treatment of Crohn's disease-related peripheral spondyloarthritis with upadacitinib: two case reports and case-based review

Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations

Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital

Immune Checkpoint Inhibitor Associated Rheumatoid Arthritis

P1594: BARICITINIB FOR STEROID-RESISTANT/RELAPSE IMMUNE THROMBOCYTOPENIA (BAITP): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL

Novel investigational drugs for alopecia areata and future perspectives

Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy

Immune checkpoint inhibitors and endocrine side effects, a narrative review

Novel Therapies for Inflammatory Bowel Disease

The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review